Presenters:
Anna Honko, Ph.D., NIH/NIAID Integrated Research Facility, Division of Clinical Research, Fort Detrick, MD
Paul Dabisch, Ph.D., National Biodefense Analysis and Countermeasures Center, US Department of Homeland Security
Description:
In vivo monitoring offers new insights into physiologic endpoints explored when characterizing animal models or evaluating the efficacy of medical countermeasures. Access to this information enables one to possibly identify disease correlates that might predict survival or differences in treatments or refine euthanasia criteria endpoints. During this one-hour session, Drs. Anna Honko and Paul Dabisch will each present findings from their studies which utilized in vivo physiologic monitoring for ebola virus in a guinea pig model and inhalational melioidosis in a nonhuman primate model, respectively.
Dr. Anna Honko will discuss outcomes from a proof-of-concept study that involved a blinded comparison of two Ebola virus variants following intraperitoneal (IP) in Hartley guinea pigs using a novel small animal remote temperature monitoring system under biocontainment conditions. Dr. Honko’s study revealed that temperature monitoring with the novel system throughout the study period showed an expected diurnal variability initially, increase in temperature during clinical phase and sharp decline prior to death/euthanasia.
In the second presentation, Dr. Paul Dabisch presents his research on the influence of aerosol particle size on the disease presentation in a nonhuman primate model of inhalational melioidosis in order to better characterize the range of potential disease manifestations that may be possible in natural exposure scenarios. The preliminary results of this study will be discussed, including comparison of fever, cytokine, and bacteremia profiles in animals exposed to large and small particle aerosols, and the utility of time domain indices of heart rate variability as a prognostic biomarker.
Lunch will be provided.